NRx Pharmaceuticals to Host Corporate and Strategic Update Conference Call on Monday, June 5, 2023

Rhea-AI Summary

NRx Pharmaceuticals, Inc. will host a corporate and strategic update conference call on June 5, 2023 at 8:30 a.m. EDT. The conference call will be available via webcast on the Company's website and a live archive will be available for 30 days. Participants can also join the call via telephone.

RADNOR, Pa., June 2, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced it will host a corporate and strategic update conference call on Monday, June 5, 2023 at 8:30 a.m. EDT.

A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/news-events/ir-calendar. An archive of the webcast will be available on the Company's website for 30 days. 

Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1 (833) 630-1956 or internationally +1 (412) 317-1837.

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically bipolar depression with suicidality and post-traumatic stress disorder (PTSD). The company's lead program NRX-101, an oral, fixed-dose combination of D-cycloserine and lurasidone, targets the brain's N-methyl-D-aspartate (NMDA) receptor and is being investigated in a Phase 2b/3 clinical trial for Suicidal Treatment-Resistant Bipolar Depression, which includes patients with both acute and sub-acute suicidality, an indication for which the only approved treatment is electroshock therapy. The company's prior Phase 2 STABIL-B clinical trial evaluating NRX-101 in patients with Severe Bipolar Depression with Acute Suicidal Ideation & Behavior (ASIB) demonstrated a substantial improvement over available therapy in reducing depression and suicidality compared to placebo when patients were treated with NRX-101 after a single dose of ketamine. Based on the findings from the STABIL-B trial, the U.S. Food and Drug Administration (FDA) granted a Special Protocol Agreement and Breakthrough Therapy Designation for NRX-101 in patients with Severe Bipolar Depression with ASIB.

 

View original content:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-to-host-corporate-and-strategic-update-conference-call-on-monday-june-5-2023-301841494.html

SOURCE NRx Pharmaceuticals, Inc.

FAQ

When will NRx Pharmaceuticals host a conference call?

NRx Pharmaceuticals will host a conference call on June 5, 2023 at 8:30 a.m. EDT.

Where can I access the webcast of the conference call?

The webcast of the conference call will be available on NRx Pharmaceuticals' website at https://ir.nrxpharma.com/news-events/ir-calendar.

How long will the webcast archive be available?

The webcast archive will be available on NRx Pharmaceuticals' website for 30 days.

How can I join the conference call via telephone?

Participants can join the conference call via telephone by dialing domestically +1 (833) 630-1956 or internationally +1 (412) 317-1837.